{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:38:49Z","timestamp":1770961129930,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T00:00:00Z","timestamp":1515024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10067-017-3953-6","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T05:30:31Z","timestamp":1515043831000},"page":"397-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effectiveness and safety of ustekinumab in na\u00efve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study"],"prefix":"10.1007","volume":"37","author":[{"given":"Maria Sole","family":"Chimenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusta","family":"Ortolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariagrazia","family":"Lorenzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Triggianese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Favero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Teoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Punzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,4]]},"reference":[{"issue":"3","key":"3953_CR1","doi-asserted-by":"publisher","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","volume":"34","author":"V Chandran","year":"2010","unstructured":"Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34(3):J314\u2013J321. https:\/\/doi.org\/10.1016\/j.jaut.2009.12.001","journal-title":"J Autoimmun"},{"issue":"10","key":"3953_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/art.24608","volume":"61","author":"G Ibrahim","year":"2009","unstructured":"Ibrahim G, Waxman R, Helliwell PS (2009) The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 61(10):1373\u20131378. https:\/\/doi.org\/10.1002\/art.24608","journal-title":"Arthritis Rheum"},{"key":"3953_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P et al (2005) Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis 64:14\u201317","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3953_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","volume":"42","author":"NJ McHugh","year":"2003","unstructured":"McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 42(6):778\u2013783. https:\/\/doi.org\/10.1093\/rheumatology\/keg217","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3953_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s10067-016-3263-4","volume":"35","author":"SP Raychaudhuri","year":"2016","unstructured":"Raychaudhuri SP, Raychaudhuri SK (2016) IL-23\/IL-17 axis in spondyloarthritis-bench to bedside. Clin Rheumatol 35(6):1437\u20131441. https:\/\/doi.org\/10.1007\/s10067-016-3263-4","journal-title":"Clin Rheumatol"},{"issue":"10","key":"3953_CR6","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/ard.2007.073569","volume":"66","author":"F Conti","year":"2007","unstructured":"Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G (2007) Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 66(10):1393\u20131397. https:\/\/doi.org\/10.1136\/ard.2007.073569","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3953_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.33321","volume":"64","author":"S Glatigny","year":"2012","unstructured":"Glatigny S, Fert I, Blaton MA, Lories RJ, Araujo LM, Chiocchia G, Breban M (2012) Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum 64(1):110\u2013120. https:\/\/doi.org\/10.1002\/art.33321","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3953_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3109\/s10165-009-0166-0","volume":"19","author":"Y Abe","year":"2009","unstructured":"Abe Y, Ohtsuji M, Ohtsuji N, Lin Q, Tsurui H, Nakae S, Shirai T, Sudo K, Hirose S (2009) Ankylosing enthesitis associated with up-regulated IFN-gamma and IL-17 production in (BXSB x NZB) F(1) male mice: a new mouse model. Mod Rheumatol 19(3):316\u2013322. https:\/\/doi.org\/10.3109\/s10165-009-0166-0","journal-title":"Mod Rheumatol"},{"issue":"7","key":"3953_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, LaFace DM, Cua DJ (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammat\u00fe CD3\u00feCD4-CD8- entheseal resident T cells. Nat Med 18(7):1069\u20131076. https:\/\/doi.org\/10.1038\/nm.2817","journal-title":"Nat Med"},{"issue":"6","key":"3953_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa062382","volume":"356","author":"GG Krueger","year":"2007","unstructured":"Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M, CNTO 1275 Psoriasis Study Group (2007) A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356(6):580\u2013592. https:\/\/doi.org\/10.1056\/NEJMoa062382","journal-title":"N Engl J Med"},{"issue":"5","key":"3953_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1185\/030079907X182112","volume":"23","author":"AB Gottlieb","year":"2007","unstructured":"Gottlieb AB, Cooper KD, McCormick TS, Toichi E, Everitt DE, Frederick B, Zhu Y, Pendley CE, Graham MA, Ann Mascelli M (2007) A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12\/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 23(5):1081\u20131092. https:\/\/doi.org\/10.1185\/030079907X182112","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"3953_CR12","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/j.0022-202X.2004.23448.x","volume":"123","author":"CL Kauffman","year":"2004","unstructured":"Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA, Pendley CE, Mascelli MA (2004) A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123(6):1037\u20131044. https:\/\/doi.org\/10.1111\/j.0022-202X.2004.23448.x","journal-title":"J Invest Dermatol"},{"issue":"9894","key":"3953_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894):780\u2013789. https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2","journal-title":"Lancet"},{"issue":"6","key":"3953_CR14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB, PSUMMIT 2 Study Group (2014) Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73(6):990\u2013999. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204655","journal-title":"Ann Rheum Dis"},{"key":"3953_CR15","doi-asserted-by":"publisher","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, Mendelsohn AM, Song M, Zhu Y, Rahman P, McInnes IB, on behalf of the PSUMMIT 1 Study Group (2015) PSUMMIT 1 study group. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res (Hoboken) 67:1739\u20131749, 12, DOI: https:\/\/doi.org\/10.1002\/acr.22645","DOI":"10.1002\/acr.22645"},{"issue":"12","key":"3953_CR16","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/acr.23000","volume":"68","author":"P Rahman","year":"2016","unstructured":"Rahman P, Puig L, Gottlieb AB, Kavanaugh A, McInnes IB, Ritchlin C, Li S, Wang Y, Song M, Mendelsohn A, Han C, PSUMMIT 1 and 2 Study Groups (2016) PSUMMIT 1 and 2 study groups. Ustekinumab treatment and improvement of physical function and health-related quality of life in patients with psoriatic arthritis. Arthritis Care Res (Hoboken) 68(12):1812\u20131822. https:\/\/doi.org\/10.1002\/acr.23000","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"3953_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10067-016-3464-x","volume":"36","author":"M Almirall","year":"2017","unstructured":"Almirall M, Rodriguez J, Mateo L, Carrascosa JM, Notario J, Gallardo F (2017) Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. Clin Rheumatol 36(2):439\u2013443. https:\/\/doi.org\/10.1007\/s10067-016-3464-x","journal-title":"Clin Rheumatol"},{"issue":"3","key":"3953_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.therap.2015.07.001","volume":"71","author":"M Michel","year":"2016","unstructured":"Michel M, Reguiai Z, Fauconier M, Brochot P, Eschard JP, Salmon JH (2016) Efficacy and safety of ustekinumab in psoriatic arthritis after anti-\u03b1 failure in routine practice. Therapie 71(3):281\u2013286. https:\/\/doi.org\/10.1016\/j.therap.2015.07.001","journal-title":"Therapie"},{"issue":"3","key":"3953_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landew\u00e9 R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Ca\u00f1ete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499\u2013510. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208337","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3953_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060\u20131071. https:\/\/doi.org\/10.1002\/art.39573","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"3953_CR21","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) CASPAR Study Group: classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3953_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"16","key":"3953_CR23","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention, Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640\u20131645. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192644","journal-title":"Circulation"},{"issue":"7","key":"3953_CR24","first-page":"946","volume":"17","author":"LH Daltroy","year":"1990","unstructured":"Daltroy LH, Larson MG, Roberts WN, Liang MH (1990) A modification of the health assessment questionnaire for the spondyloarthropathies. J Rheumatol 17(7):946\u2013950","journal-title":"J Rheumatol"},{"issue":"4","key":"3953_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","volume":"51","author":"RG Langley","year":"2004","unstructured":"Langley RG, Ellis CN (2004) Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician\u2019s global assessment. J Am Acad Dermatol 51(4):563\u2013569. https:\/\/doi.org\/10.1016\/j.jaad.2004.04.012","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3953_CR26","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell PS, Fitzgerald O, Fransen J et al (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72(6):986\u2013989. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201341","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3953_CR27","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS (2008) Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Care Res 59(5):686\u2013691. https:\/\/doi.org\/10.1002\/art.23568","journal-title":"Arthritis Care Res"},{"issue":"7","key":"3953_CR28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/acr.20155","volume":"62","author":"L Coates","year":"2010","unstructured":"Coates L, Helliwell P (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 62(7):965\u2013969. https:\/\/doi.org\/10.1002\/acr.20155","journal-title":"Arthritis Care Res"},{"key":"3953_CR29","unstructured":"http:\/\/www.ema.europa.eu\/docs\/it_IT\/document_library\/EPAR__Product_Information\/human\/000958\/WC500058513.pdf"},{"issue":"3","key":"3953_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3899\/jrheum.110763","volume":"39","author":"S Iervolino","year":"2012","unstructured":"Iervolino S, Di Minno MN, Peluso R et al (2012) Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-\u03b1 blockers. J Rheumatol 39(3):568\u2013573. https:\/\/doi.org\/10.3899\/jrheum.110763","journal-title":"J Rheumatol"},{"issue":"10","key":"3953_CR31","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s10067-017-3769-4","volume":"36","author":"MS Chimenti","year":"2017","unstructured":"Chimenti MS, Triggianese P, Conigliaro P, Tonelli M, Gigliucci G, Novelli L, Teoli M, Perricone R (2017) A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. Clin Rheumatol 36(10):2253\u20132260. https:\/\/doi.org\/10.1007\/s10067-017-3769-4","journal-title":"Clin Rheumatol"},{"issue":"12","key":"3953_CR32","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1007\/s10067-016-3425-4","volume":"35","author":"SM Reddy","year":"2016","unstructured":"Reddy SM, Crean S, Martin AL, Burns MD, Palmer JB (2016) Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature. Clin Rheumatol 35(12):2955\u20132966. https:\/\/doi.org\/10.1007\/s10067-016-3425-4","journal-title":"Clin Rheumatol"},{"issue":"6","key":"3953_CR33","first-page":"1051","volume":"34","author":"A Marchesoni","year":"2016","unstructured":"Marchesoni A, Lubrano E, Manara M, Ramonda R, Salvarani C, Olivieri I (2016) Current approach to the management of psoriatic arthritis according to a sample of Italian rheumatologists. Clin Exp Rheumatol 34(6):1051\u20131058","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"3953_CR34","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s10067-017-3700-z","volume":"36","author":"M Napolitano","year":"2017","unstructured":"Napolitano M, Costa L, Caso F, Megna M, Scarpa R, Balato N, Ayala F, Balato A (2017) Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. Clin Rheumatol 36(7):1589\u20131593. https:\/\/doi.org\/10.1007\/s10067-017-3700-z","journal-title":"Clin Rheumatol"},{"issue":"2","key":"3953_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00296-016-3590-4","volume":"37","author":"S Zhao","year":"2017","unstructured":"Zhao S, Challoner B, Khattak M, Moots RJ, Goodson NJ (2017) Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. Rheumatol Int 37(2):239\u2013244. https:\/\/doi.org\/10.1007\/s00296-016-3590-4","journal-title":"Rheumatol Int"},{"issue":"10","key":"3953_CR36","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, Ward MM, Reveille JD, Gensler LS (2013) The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65(10):2645\u20132654. https:\/\/doi.org\/10.1002\/art.38070","journal-title":"Arthritis Rheum"},{"issue":"12","key":"3953_CR37","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","volume":"55","author":"P H\u00f8jgaard","year":"2016","unstructured":"H\u00f8jgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L (2016) The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford) 55(12):2191\u20132199. https:\/\/doi.org\/10.1093\/rheumatology\/kew326","journal-title":"Rheumatology (Oxford)"},{"key":"3953_CR38","unstructured":"Rosas J, Llinares-Tello F, Senabre-Gallego JM, Barber-Vall\u00e9s X, Santos-Soler G, Salas-Heredia E, Pons Bas A, Cano P\u00e9rez C, Garc\u00eda-Carrasco M, and the AIRE-MB Group (2017) The AIRE-MB group. Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. Clin Exp Rheumatol 35:145\u2013148, 1"},{"issue":"4","key":"3953_CR39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite A, Raffayov\u00e1 H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N, RESPOND investigators (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71(4):541\u2013548. https:\/\/doi.org\/10.1136\/ard.2011.152223","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3953_CR40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrrheum.2016.183","volume":"12","author":"L Gossec","year":"2016","unstructured":"Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS (2016) Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol 12(12):743\u2013750. https:\/\/doi.org\/10.1038\/nrrheum.2016.183","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"3953_CR41","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/art.39626","volume":"68","author":"M Ghiti Moghadam","year":"2016","unstructured":"Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM et al (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 68(8):1810\u20131817. https:\/\/doi.org\/10.1002\/art.39626","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"3953_CR42","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.autrev.2011.04.015","volume":"10","author":"MS Chimenti","year":"2011","unstructured":"Chimenti MS, Graceffa D, Perricone R (2011) Anti-TNF\u03b1 discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev 10(10):636\u2013640. https:\/\/doi.org\/10.1016\/j.autrev.2011.04.015","journal-title":"Autoimmun Rev"},{"issue":"6","key":"3953_CR43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14740338.2017.1323864","volume":"16","author":"A L\u00f3pez-Ferrer","year":"2017","unstructured":"L\u00f3pez-Ferrer A, Laiz A, Puig L (2017) The safety of ustekinumab for the treatment of psoriatic arthritis. Expert Opin Drug Saf 16(6):733\u2013734. https:\/\/doi.org\/10.1080\/14740338.2017.1323864","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"3953_CR44","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","volume":"75","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, Song M, Randazzo B, Rahman P, McInnes IB (2016) Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2). Ann Rheum Dis 75(11):1984\u20131988. https:\/\/doi.org\/10.1136\/annrheumdis-2015-209068","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3953-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3953-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3953-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T10:38:17Z","timestamp":1751193497000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3953-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3953"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3953-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,4]]}}}